AwesomeCapital
Search This Blog
Thursday, December 5, 2019
Analyst actions, Dec. 5
NextCure (NASDAQ:
NXTC
) initiated with Buy rating and $72 (41% upside) price target at Needham.
X4 Pharmaceuticals (NASDAQ:
XFOR
) initiated with Buy rating and $25 (146% upside) price target at B. Riley FBR.
https://seekingalpha.com/news/3523967-b-riley-sees-146-upside-in-x4-pharma-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.